How cagrilintide works
Cagrilintide's weight-loss effect begins in a tiny brainstem region called the area postrema, a natural sensor for appe…
The brainstem switch for fullness
Cagrilintide's weight-loss effect begins in a tiny brainstem region called the area postrema, a natural sensor for appetite hormones in the blood. From there the fullness signal spreads upward into the brain's energy-balance circuitry.
This unit traces that signal from receptor to behavior, shows exactly where it acts in the body, and explains why acting through a distinct circuit is what lets cagrilintide add to GLP-1 rather than merely duplicate it.
Key terms
Where the signal starts
The area postrema is a small region at the base of the brainstem with an unusual property: its blood-brain barrier is leaky, so it can directly sense hormones circulating in the blood. This makes it the brain's frontline sensor for satiety signals, and it is densely packed with amylin receptors.
What makes this circuit compelling is the strength of the evidence. In rodents, selectively removing amylin receptors from the area postrema abolishes amylin's appetite-suppressing effect, and restoring them brings it back. That "necessary and sufficient" result pins the drug's core action to a specific, identifiable brain structure rather than a vague systemic effect.
AdvancedWhy a leaky barrier matters
Most of the brain is shielded from blood-borne peptides by the blood-brain barrier, so a large circulating peptide like cagrilintide cannot simply diffuse in everywhere. The area postrema is a circumventricular organ with fenestrated capillaries, so it can sample the blood directly. That anatomical quirk is why a big, albumin-bound peptide can still act centrally: it does not need to cross the barrier, it acts where the barrier is already open.